A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
Public ClinicalTrials.gov record NCT00412113. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia.
Study identification
- NCT ID
- NCT00412113
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 245 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Apr 2008 (Actual)
- Completion
- Apr 2008 (Actual)
- Last update posted
- Feb 11, 2021
2007 – 2008
United States locations
- U.S. sites
- 51
- U.S. states
- 23
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35209 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35216 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35234 | — |
| Pfizer Investigational Site | Mesa | Arizona | 85206 | — |
| Pfizer Investigational Site | Garden Grove | California | 92843 | — |
| Pfizer Investigational Site | Mission Viejo | California | 92692 | — |
| Pfizer Investigational Site | Rancho Santa Margarita | California | 92688 | — |
| Pfizer Investigational Site | Torrance | California | 90502 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32605 | — |
| Pfizer Investigational Site | Kissimmee | Florida | 34741 | — |
| Pfizer Investigational Site | Melbourne | Florida | 32935 | — |
| Pfizer Investigational Site | Miami | Florida | 33176 | — |
| Pfizer Investigational Site | Safety Harbor | Florida | 34695 | — |
| Pfizer Investigational Site | St. Petersburg | Florida | 33701 | — |
| Pfizer Investigational Site | Augusta | Georgia | 30904 | — |
| Pfizer Investigational Site | Tucker | Georgia | 30084 | — |
| Pfizer Investigational Site | South Bend | Indiana | 46601 | — |
| Pfizer Investigational Site | Erlanger | Kentucky | 41018 | — |
| Pfizer Investigational Site | Auburn | Maine | 04210 | — |
| Pfizer Investigational Site | Warren | Michigan | 48091 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55404 | — |
| Pfizer Investigational Site | Chesterfield | Missouri | 63017 | — |
| Pfizer Investigational Site | Florissant | Missouri | 63031 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68116-2004 | — |
| Pfizer Investigational Site | Henderson | Nevada | 89014 | — |
| Pfizer Investigational Site | Henderson | Nevada | 89015 | — |
| Pfizer Investigational Site | Belvidere | New Jersey | 07823 | — |
| Pfizer Investigational Site | Bridgewater | New Jersey | 08807 | — |
| Pfizer Investigational Site | Clifton | New Jersey | 07013 | — |
| Pfizer Investigational Site | Elizabeth | New Jersey | 07202 | — |
| Pfizer Investigational Site | Hillsborough | New Jersey | 08844 | — |
| Pfizer Investigational Site | Trenton | New Jersey | 08618 | — |
| Pfizer Investigational Site | Brooklyn | New York | 11229 | — |
| Pfizer Investigational Site | Buffalo | New York | 14209 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45242 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73103 | — |
| Pfizer Investigational Site | Tulsa | Oklahoma | 74136 | — |
| Pfizer Investigational Site | Bensalem | Pennsylvania | 19020 | — |
| Pfizer Investigational Site | Lansdale | Pennsylvania | 19446 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19146 | — |
| Pfizer Investigational Site | Providence | Rhode Island | 02904 | — |
| Pfizer Investigational Site | Goose Creek | South Carolina | 29445 | — |
| Pfizer Investigational Site | Mt. Pleasant | South Carolina | 29464 | — |
| Pfizer Investigational Site | Bristol | Tennessee | 37620 | — |
| Pfizer Investigational Site | Kingsport | Tennessee | 37660 | — |
| Pfizer Investigational Site | Dallas | Texas | 75235 | — |
| Pfizer Investigational Site | Houston | Texas | 77030-2324 | — |
| Pfizer Investigational Site | Plano | Texas | 75093 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78238 | — |
| Pfizer Investigational Site | Chesapeake | Virginia | 23320 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00412113, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2021 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00412113 live on ClinicalTrials.gov.